Lovy Pradeep

Director, Program Management @Bioxcel Therapeutics, Inc

BioXcel Therapeutics, Inc.(BTAI) is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology. BTAI focuses on utilizing cutting-edge technology & innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BTAI employs a unique AI platform in an effort to reduce therapeutic development costs and potentially accelerate timelines, while aiming to increase the possibility of success. This approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTAI believes that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.